

Covalon To Showcase MediClear™ Preop At Aats 2018 Annual Meeting

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Apr. 30, 2018-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be showcasing its perioperative suite of innovative products, including MediClear™ PreOp, at the American Association for Thoracic Surgery ("AATS") Annual Meeting.

MediClear PreOp is the market's first breathable and transparent antimicrobial self-adherent silicone drape for preoperative skin. Its polyurethane barrier film acts as a protective barrier to isolate a procedural site from external contamination, and its silicone adhesive provides a rapid bactericidal and fungicidal effect against a broad spectrum of microorganisms, averaging a 99.99% reduction after 30 minutes, and preventing their regrowth for days before a surgical procedure.

"Cardiothoracic surgeons and their patients are a critically important user group for our perioperative line of products." said Brian Pedlar, Covalon's Chief Executive Officer. "Both MediClear PreOp and SurgiClear™ bring breakthrough technology to the fight against surgical site infections during cardiothoracic procedures. Reducing surgical site infections has a profoundly positive cost impact on surgeons and healthcare institutions. MediClear PreOp and SurgiClear protect patients before and after their surgical procedures."

The AATS Annual Meeting is the primary opportunity for cardiothoracic surgeons and their teams to receive continuing medical education and learn about the latest products and services in cardiothoracic treatment and care.

Covalon will be showcasing its unique perioperative line of self-adherent silicone products that aid in the management of surgical incisions. These include the recently FDA-cleared MediClear™ PreOp, SurgiClear™, a dual antimicrobial transparent dressing proven to have a synergistic effect against some of the most common surgical site infection bacteria¹, and MediClear™ Scar, a single-use discreet film dressing designed to help prevent and manage and reduce the severity of an incision scar.

Visit Covalon at booth 341 at the AATS Annual Meeting during exhibit hours between April 29th through May 1st, at the San Diego Convention Center in San Diego, CA

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

¹A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180430005845/en/>

Source: Covalon

Covalon Technologies Ltd.
Brian Pedlar, CEO,
bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

<https://ir.covalon.com/press-releases?item=136>